Safety profile of upadacitinib: Descriptive analysis in over 27,000 patient‑years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease
Adv Ther 2025 Doi: 10.1007/s12325-025-03328-y Epub ahead of print
This descriptive analysis indicates a long-term safety profile of UPA consistent with previous reports, further supporting long-term treatment of chronic diseases with UPA. Burmester at al. characterized the safety profile of UPA across multiple approved indications and offer insights into its long-term use to help inform clinical decision-making.
Variations in TEAE rates across indications likely reflected differences in populations and underlying comorbidities. Findings from this analysis can provide clinicians with a comprehensive understanding of the long-term safety profile of UPA, enabling more informed treatment decisions tailored to individual patient needs.
Keywords:
